Mucormycosis: Review on the basis of Diagnosis Treatment, Preventive Measures, and Recent Research Approach

Warude Bhagyashri; Gugale Prachi; Jadhav Manasi; Garud Aniket; Meshram Priti; S.N. Wagh

doi:10.37591/rrjomst.v10i3.2734

Abstract

Mucormycosis is a fungal infection called an angio-invasive disease due to invasion of fungi of the order Mucorales and zygomatic species which causes tissue infarction and necrosis. The main aim and purpose of this review are related to the overview of Etiopathogenesis of Mucormycosis, mortality due to various types of Mucormycosis, recent advances in diagnostic and treatment methods, and their diagnostic preventive measures. It shows serious and worrying mortality and morbidity rates. The Etiopathogenesis of the disease remains different overall in the world and the diagnosis of the disease's appearance remains a critical role for the clinicians. It is a fatal fungal infection that mainly affects altered immunity patients and is mostly found in recent pandemic disease COVID-19 patients at recovery phase, also in people with high diabetics and taking prolonged corticosteroids. The liposomal Amphotericin-B (>5mg /kg) is the newest drug that is recommended as first-line therapy. Intravenous Isavuconazole and Posaconazole are delayed-release tablet forms used for patients intolerant to Amphotericin-B as a second-line of treatment. The review mentions the recent treatment and management of the Mucormycosis Viewpoints are however hopeful and promising for researchers for new drug therapy evaluating relationships between host, fungi, and antifungal drugs, immune-boosting agents and new routes of administration such as aerosols may improve mucormycosis treatment. Tests for identification include the Galactomannan test and the Beta Glucan test. Both these tests are found to be negative in the case of mucormycosis.

Abstract

Keywords